Sight Sciences Files 8-K Report

TL;DR

Sight Sciences filed an 8-K, likely with important updates. Check the full filing.

AI Summary

On May 30, 2024, Sight Sciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or financial figures within the provided text. The report confirms the company's identity, incorporation in Delaware, and principal executive offices in Menlo Park, California.

Why It Matters

This 8-K filing indicates a material event has occurred for Sight Sciences, Inc., requiring public disclosure. Investors should review the full filing for details on the nature of these 'Other Events'.

Risk Assessment

Risk Level: medium — An 8-K filing signifies a material event, which could have significant implications for the company's stock price and future prospects.

Key Players & Entities

• Sight Sciences, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Menlo Park, California (location) — Principal Executive Offices
• May 30, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT The Nasdaq

Filing Documents

• sght-20240530.htm (8-K) — 44KB
• 0000950170-24-066276.txt ( ) — 164KB
• sght-20240530.xsd (EX-101.SCH) — 26KB
• sght-20240530_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events On May 30, 2024, five Medicare Administrative Contractors ("MACs"), Palmetto GBA, Celerian Group Company, National Government Services, Noridian Healthcare Solutions, and WPS Insurance Corporation, each individually published proposed local coverage determinations and related draft local coverage articles (collectively, the "Draft LCDs") regarding Micro-Invasive Glaucoma Surgery ("MIGS"). While each of the Draft LCDs identify certain procedures as medically necessary in patients over the age of 18 for glaucoma management when the applicable coverage limitations are met, the Draft LCDs do not propose to adopt specific coverage criteria for canaloplasty in combination with trabeculotomy ab interno which is a procedural description associated with the Company's OMNI Surgical System ("OMNI") nor goniotomy, which is a procedural description associated with the Company's SION Surgical Instrument ("SION") technology. If these Draft LCDs become effective in their current form, procedures for canaloplasty in combination with trabeculotomy ab interno and goniotomy procedures would continue to be eligible for Medicare coverage in the states covered by these MACs. The states covered by these five MACs accounted for an aggregate of approximately 62% of the Company's Surgical Glaucoma revenue in 2023. The Draft LCDs each propose to adopt non-coverage policies when an aqueous shunt or stent procedure is performed in combination with a surgical MIGS procedure (such as canaloplasty or goniotomy) at the same time of service in the same patient eye. Each MAC will have a 45-day comment period on the Draft LCDs, wherein stakeholders may provide feedback on the policies via written responses and oral feedback during open meetings held during each comment period. At the conclusion of the comment period, each MAC will review and respond to comments received, and may make changes to the Draft LCDs before it is finalized within 365 days from the original public

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: May 30, 2024 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR